{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:01:38Z","timestamp":1785232898589,"version":"3.55.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypopituitarism is associated with adverse body composition and steatotic liver disease, particularly when the growth hormone\/insulin-like growth factor-1 (GH\/IGF-1) axis is disturbed. Progression to decompensated cirrhosis is uncommon, and published reports do not establish a direct causal relationship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 37-year-old woman presented with jaundice, massive ascites, splenomegaly, thrombocytopenia, hypoalbuminemia, coagulopathy, and hyponatremia. She had undergone pituitary adenoma surgery at approximately 12 years of age, followed by amenorrhea and more than two decades without regular endocrine follow-up or hormone replacement. The clinical and biochemical profile supported long-standing panhypopituitarism. Possible central HPA-axis dysfunction was present; secondary adrenal insufficiency was clinically probable but not dynamically confirmed. Other features included central hypothyroidism, hypogonadotropic hypogonadism, low prolactin, central diabetes insipidus, and severe GH\/IGF-1 axis disturbance. GH stimulation testing was not performed, and interpretation of the GH\/IGF-1 axis was confounded by advanced liver disease. Common viral, autoimmune, alcohol-related, drug-related, and overt cardiac causes were not supported. However, transferrin saturation was 94.6%, and iron overload, Wilson disease, alpha-1 antitrypsin deficiency, and histological metabolic steatohepatitis were not fully excluded. Liver biopsy supported advanced fibrosis\/cirrhosis, and explant pathology showed micronodular cirrhosis with hepatocellular cholestasis. She underwent liver transplantation in May 2026. Aminotransferase levels subsequently declined, but persistent thrombocytopenia, pulmonary infection, and acute kidney injury requiring hemodialysis developed. She progressed to septic shock and died more than 20 days after transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-standing untreated panhypopituitarism may have contributed to metabolic and fibrogenic risk in this patient, but incomplete etiological evaluation precluded a definitive causal link. Lifelong endocrine follow-up and attention to liver health are warranted after pituitary surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1899455","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:35:09Z","timestamp":1785231309000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Liver transplantation for decompensated cirrhosis of uncertain etiology in a woman with long-standing untreated panhypopituitarism: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Lu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of General Practice, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of General Practice, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Sun Yat-Sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longliu","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of General Practice, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People\u2019s Hospital","place":["Shenzhen, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: An endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071447","article-title":"The role of growth hormone and insulin-like growth factor-I in the liver","volume":"18","author":"Takahashi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac088","article-title":"Growth hormone and insulin-like growth factor 1 regulation of nonalcoholic fatty liver disease","volume":"107","author":"Dichtel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1953","article-title":"Growth hormone deficiency and NAFLD: An overlooked and underrecognized link","volume":"6","author":"Doycheva","year":"2022","journal-title":"Hepatol Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i14.1741","article-title":"Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients","volume":"25","author":"Yuan","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1057769","article-title":"Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma","volume":"13","author":"Hwang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4753-24","article-title":"Decompensated cirrhosis with hepatopulmonary syndrome in a patient with interrupted treatment for hypopituitarism: A case report","volume":"64","author":"Tadokoro","year":"2025","journal-title":"Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.235.61","article-title":"Long-term survival with growth hormone replacement after liver transplantation of pediatric nonalcoholic steatohepatitis complicating acquired hypopituitarism","volume":"235","author":"Fujio","year":"2015","journal-title":"Tohoku J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/petr.12819","article-title":"Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism","volume":"20","author":"Gilliland","year":"2016","journal-title":"Pediatr Transplant"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.928004","article-title":"A case of hypopituitarism complicated by non-alcoholic steatohepatitis and severe pulmonary hypertension","volume":"22","author":"Suzuki","year":"2021","journal-title":"Am J Case Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244805","article-title":"Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism","volume":"14","author":"Alabsawy","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1297146","article-title":"Pituitary stalk interruption syndrome and liver cirrhosis associated with diabetes and an inactivating KCNJ11 gene mutation: a case report and literature review","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1407686","article-title":"Hepatopulmonary syndrome secondary to metabolic associated fatty liver disease in childhood\u2014novel treatment with growth hormone replacement therapy: a case report and systematic review of literature","volume":"15","author":"Choe","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jhep.2022.03.033","article-title":"EASL clinical practice guidelines on haemochromatosis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32805","article-title":"A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 practice guidance from the American Association for the Study of Liver Diseases","volume":"77","author":"Schilsky","year":"2023","journal-title":"Hepatology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899455\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:35:10Z","timestamp":1785231310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1899455\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":16,"alternative-id":["10.3389\/fendo.2026.1899455"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1899455","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1899455"}}